论文部分内容阅读
类风湿关节炎(RA)病理机制未明,目前对RA的治疗主要集中在控制疼痛和炎症、阻断骨质破坏的发展以及改善关节功能上~(〔1〕)。传统治疗药物由于其系统用药的特性,在治疗的同时也产生一定的不良反应。白三烯(LT)B4是白细胞产生的一种脂质介质,系膜磷脂在磷脂酶(PL)A2作用下的花生四烯酸(AA)下游产物。研究证明在RA患者的关节腔和滑液中存在高浓度的LTB4,且大量文献证明LTB4在RA的发病机制中发
The pathogenesis of rheumatoid arthritis (RA) is unknown. The current treatment of RA focuses on the control of pain and inflammation, the development of bone destruction, and the improvement of joint function (1). Traditional therapeutic drugs due to the characteristics of its systemic medication, but also in the treatment of certain adverse reactions. Leukotriene (LT) B4 is a lipid medium produced by leukocytes, a downstream product of arachidonic acid (AA) of mesangial phospholipids under the action of phospholipase (PL) A2. Studies have shown that there is a high concentration of LTB4 in joint cavities and synovial fluid in RA patients and a large body of literature has demonstrated that LTB4 is involved in the pathogenesis of RA